scholarly journals Clinico-genetic findings in 509 frontotemporal dementia patients

Author(s):  
Matias Wagner ◽  
Georg Lorenz ◽  
Alexander E. Volk ◽  
Theresa Brunet ◽  
Dieter Edbauer ◽  
...  

AbstractFrontotemporal dementia (FTD) is a clinically and genetically heterogeneous disorder. To which extent genetic aberrations dictate clinical presentation remains elusive. We investigated the spectrum of genetic causes and assessed the genotype-driven differences in biomarker profiles, disease severity and clinical manifestation by recruiting 509 FTD patients from different centers of the German FTLD consortium where individuals were clinically assessed including biomarker analysis. Exome sequencing as well as C9orf72 repeat analysis were performed in all patients. These genetic analyses resulted in a diagnostic yield of 18.1%. Pathogenic variants in C9orf72 (n = 47), GRN (n = 26), MAPT (n = 11), TBK1 (n = 5), FUS (n = 1), TARDBP (n = 1), and CTSF (n = 1) were identified across all clinical subtypes of FTD. TBK1-associated FTD was frequent accounting for 5.4% of solved cases. Detection of a homozygous missense variant verified CTSF as an FTD gene. ABCA7 was identified as a candidate gene for monogenic FTD. The distribution of APOE alleles did not differ significantly between FTD patients and the average population. Male sex was weakly associated with clinical manifestation of the behavioral variant of FTD. Age of onset was lowest in MAPT patients. Further, high CSF neurofilament light chain levels were found to be related to GRN-associated FTD. Our study provides large-scale retrospective clinico-genetic data such as on disease manifestation and progression of FTD. These data will be relevant for counseling patients and their families.

2016 ◽  
Vol 3 (8) ◽  
pp. 623-636 ◽  
Author(s):  
Lieke H. Meeter ◽  
Elise G. Dopper ◽  
Lize C. Jiskoot ◽  
Raquel Sanchez-Valle ◽  
Caroline Graff ◽  
...  

2020 ◽  
Vol 16 (S5) ◽  
Author(s):  
Ignacio Illán‐Gala ◽  
Alberto Lleó ◽  
Anna M. Karydas ◽  
Adam M. Staffaroni ◽  
Henrik Zetterberg ◽  
...  

BMC Neurology ◽  
2013 ◽  
Vol 13 (1) ◽  
Author(s):  
Maria Landqvist Waldö ◽  
Alexander Frizell Santillo ◽  
Ulla Passant ◽  
Henrik Zetterberg ◽  
Lars Rosengren ◽  
...  

2019 ◽  
Vol 18 (12) ◽  
pp. 1103-1111 ◽  
Author(s):  
Emma L van der Ende ◽  
Lieke H Meeter ◽  
Jackie M Poos ◽  
Jessica L Panman ◽  
Lize C Jiskoot ◽  
...  

2017 ◽  
Vol 13 (7S_Part_15) ◽  
pp. P751-P752 ◽  
Author(s):  
Jessica L. Panman ◽  
Emma Louise van der Ende ◽  
Lieke H.H. Meeter ◽  
Mark J.R.J. Bouts ◽  
Elise G.P. Dopper ◽  
...  

Neurology ◽  
2016 ◽  
Vol 87 (13) ◽  
pp. 1329-1336 ◽  
Author(s):  
Jonathan D. Rohrer ◽  
Ione O.C. Woollacott ◽  
Katrina M. Dick ◽  
Emilie Brotherhood ◽  
Elizabeth Gordon ◽  
...  

2020 ◽  
Author(s):  
Nicholas Ashton ◽  
Shorena Janelidze ◽  
Ahmad Al Khleifat ◽  
Antoine Leuzy ◽  
Emma van der Ende ◽  
...  

Abstract Increased cerebrospinal fluid neurofilament light (NfL) is a recognized biomarker for neurodegeneration that can also be assessed in blood. Here, we investigate plasma NfL as a marker of neurodegeneration in fifteen neurodegenerative diseases from two multicenter cohorts: King’s College London (n = 847) and the Swedish BioFINDER study (n = 1464). Plasma NfL was significantly increased in all cortical neurodegenerative disorders, amyotrophic lateral sclerosis and atypical parkinsonian disorders. We further demonstrate that plasma NfL is clinically useful in identifying, i) atypical parkinsonian disorders in patients with parkinsonism, ii) dementia in individuals with Down Syndrome, iii) detect cases of frontotemporal dementia among psychiatric disorders such as moderate and severe depression, iv) identify frontotemporal dementia in patients with cognitive impairment. Data-driven cut-offs highlighted the fundamental importance of age-related plasma NfL cut-offs for disorders with a younger age of onset. Finally, our findings suggest that plasma NfL performs best when a concentration cut-off is applied to indicate no underlying neurodegeneration, with low false positives, in all age-related cut-offs.


2017 ◽  
Vol 13 (7) ◽  
pp. P1228-P1229
Author(s):  
Lieke H.H. Meeter ◽  
Tania F. Gendron ◽  
Ana C. Sias ◽  
Lize C. Jiskoot ◽  
Caroline Graff ◽  
...  

2019 ◽  
Vol 113 ◽  
pp. 137-140 ◽  
Author(s):  
MHD Rami Al Shweiki ◽  
Petra Steinacker ◽  
Patrick Oeckl ◽  
Bastian Hengerer ◽  
Adrian Danek ◽  
...  

2020 ◽  
pp. jnnp-2020-323520
Author(s):  
Imogen Joanna Swift ◽  
Aitana Sogorb-Esteve ◽  
Carolin Heller ◽  
Matthis Synofzik ◽  
Markus Otto ◽  
...  

The frontotemporal dementia (FTD) spectrum of neurodegenerative disorders includes a heterogeneous group of conditions. However, following on from a series of important molecular studies in the early 2000s, major advances have now been made in the understanding of the pathological and genetic underpinnings of the disease. In turn, alongside the development of novel methodologies for measuring proteins and other molecules in biological fluids, the last 10 years have seen a huge increase in biomarker studies within FTD. This recent past has focused on attempting to develop markers that will help differentiate FTD from other dementias (particularly Alzheimer’s disease (AD)), as well as from non-neurodegenerative conditions such as primary psychiatric disorders. While cerebrospinal fluid, and more recently blood, markers of AD have been successfully developed, specific markers identifying primary tauopathies or TDP-43 proteinopathies are still lacking. More focus at the moment has been on non-specific markers of neurodegeneration, and in particular, multiple studies of neurofilament light chain have highlighted its importance as a diagnostic, prognostic and staging marker of FTD. As clinical trials get under way in specific genetic forms of FTD, measures of progranulin and dipeptide repeat proteins in biofluids have become important potential measures of therapeutic response. However, understanding of whether drugs restore cellular function will also be important, and studies of key pathophysiological processes, including neuroinflammation, lysosomal function and synaptic health, are also now becoming more common. There is much still to learn in the fluid biomarker field in FTD, but the creation of large multinational cohorts is facilitating better powered studies and will pave the way for larger omics studies, including proteomics, metabolomics and lipidomics, as well as investigations of multimodal biomarker combinations across fluids, brain imaging and other domains. Here we provide an overview of the past, present and future of fluid biomarkers within the FTD field.


Sign in / Sign up

Export Citation Format

Share Document